U.S. Markets close in 3 hrs 34 mins

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
224.33-14.22 (-5.96%)
As of 12:26PM EDT. Market open.
Sign in to post a message.
  • t
    tan john
    Zacks had given BNTX a Momentum Style Score of B and had rank BNTX as a #1(Strong Buy) stock. and such stock wiĺ likely outperfotm
  • m
    michael
    Ugur Sahin and Özlem TüreciBiontech founders hopeful in the fight against cancer
    June 13, 2021

    ...Depending on how the project, which has been running for a long time, ended up, Sahin continued, some of the product candidates could be ready by 2023 to submit dossiers for approval.

    https://www.deutschlandfunk.de/ugur-sahin-und-oezlem-tuereci-biontech-gruender.1939.de.html?drn:news_id=1269289
  • D
    Dick
    B of A is now bearish on Moderna saying the run is over. Moderna focused heavily on the US and fell behind in the rest of the world. I wonder if that caused the negative comments today? Of course B of A has been a laggard in following COVID vaccine stocks so maybe this won’t damage MRNA.
  • W
    Wim
    Almost a third of patients who died after catching Indian ‘delta’ variant had BOTH jabs as fears of third wave grow (Sun, UK)
  • D
    Damola
    @DT, as an obvious NVAX bull why not stay on NVAX board? Why do you keep lurking around BNTX board?
    A lot of information you are posting on here could be useful for your fellow NVAX longs.
  • I
    ItsMeLayla
    Fosun to start BioNTech production in Shanghai in August
  • v
    von Liebenstein
    Buy some more at a beautiful discount. I just did.
    Bullish
  • D
    Dick
    Both MRNA and BNTX down today. Market watch says “possibly” due to a NVAX PR on a Phase. 3 test. This will settle down as NVAX has not yet submitted complete data for a possible approval in Q3.
  • T
    Tozinameran
    Don’t sell at 250. It’s an artificial psychological resistance level, not a technical resistance level.
  • D
    DT
    On NVAX data release "Once the production process is in place, the vaccine offers potential advantages. Its manufacturing process is familiar to vaccine manufacturers and its deployment in the field is relatively simple since it can be stored in a refrigerator, several scientists said.

    “The benefit of their formulation … is it’s remarkably scalable, so they can scale to a very high number of doses,” said Matthew Frieman, a coronavirus expert at the U-Md. School of Medicine who began collaborating with the company in 2012, on a vaccine for a different coronavirus, Middle East respiratory syndrome. “It’s not a super-strange production platform … you don’t need super-specialized facilities. It’s stable, so you don’t need severe cold chain” to store the vaccine."
  • I
    ItsMeLayla
    Novavax is a Scam
    RELATED: Novavax COVID-19 vaccine 90% efficacious in phase 3, but protection plummets against one variant

    This was through 60 days of follow-up. However, with additional follow-up, “the complete analysis of the South Africa trial indicates that there may be a modest protective effect of prior exposure with the original COVID-19 strain,” it added.

    This effectiveness is however lower than the data at the start of the year, which showed efficacy of just over 60% against symptomatic COVID in the South African trial. Though this was more mixed, with some having an early form of the virus as well as having the South African variant among those who were HIV-negative.

    Back in January, Novavax’s vaccine achieved 89.3% efficacy in a phase 3 clinical trial that enrolled subjects exposed to the B.1.1.7 variant found in the U.K., a variant that has higher transmissibility but is not seen as being able to evade vaccines nor more lethal.
    Bullish
  • G
    GR8INFO4U
    Just to give you an idea of deliveries for Q2 and why Q2 is going to be a fantastic Earnings quarter
    EU is anticiipated to get about 250mln doses in total - Germany Confirms on Target for its portion 50mln doses.

    The ministry spokesman said that Germany will receive 50.3 million doses of the Pfizer-BioNTech vaccine in the second quarter, Moderna would ship 6.4 million and AstraZeneca 12.4 million, all fulfilling their supply commitments.
  • I
    Investorgate
    BNTX’s mRNA Technology is the best and safest! Novavax is tied up to $1.6billion from warp speed funding, (insiders have been cashing in) Their DNA technology is also scary indeed! Today’s news will be old news by tomorrow, they’re way behind and won’t have the manufacturing capabilities needed anyway.
  • I
    ItsMeLayla
    Monday $300.....China here we Come via Fuson!
    Watch Fuson & Premarket on Monday I think we are going to see a New High
    Bullish
  • e
    e
    So what is expected this week? Are we going to hit $270 by Friday?
    Also where are those analysis, we are at their high target, aren’t they supposed to announce new -high- targets just about now?
  • D
    Dick
    Reality check update: With an expected EPS by consensus of $8.96 for Q 2 to be confirmed soon, that puts BNTX forward P/E at around 6.80 based on our current SP. Somethings got to give very soon. JMHO
  • M
    Matthew
    BNTX expanding into Africa to produce vaccines on the continent by 2024 per Financial Times.
  • I
    ItsMeLayla
    To me it looks like Moderna & BioNTech will be the Two Vaccines of highest demand. Gr8 info has been right about both Moderna & BioNTech, and May even think about putting some money into Moderna as at looks like Novovax is going to be put to bed and the demand for mRNA will surge. I also think that J&J will replace AstraZeneca due to there inability to provide efficacy data for the South African variant & there supply constraints
    Bullish
  • l
    lee
    I guess today the stock will remain the same as yesterday? It seems like CDC is trying to create a topic and i think majority of the investors are familiar with mRNA vaccine.